Search company, investor...

Founded Year

1997

Stage

Acquired | Acquired

Total Raised

$11.87M

Valuation

$0000 

About Dextera Surgical

Dextera Surgical, fka Cardica, strives to improve the methods and results of cardiac bypass surgery through innovative surgical tool design. The company's technologies technologies are designed to enable minimally invasive and robotic-assisted surgery.

Headquarters Location

900 Saginaw Drive

Redwood City, California, 94063,

United States

650-364-9975

Loading...

Loading...

Expert Collections containing Dextera Surgical

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Dextera Surgical is included in 2 Expert Collections, including Robotics.

R

Robotics

1,974 items

This collection includes startups developing autonomous ground robots, unmanned aerial vehicles, robotic arms, and underwater drones, among other robotic systems. This collection also includes companies developing operating systems and vision modules for robots.

D

Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Dextera Surgical Patents

Dextera Surgical has filed 8 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/23/2016

11/28/2017

Surgical removal procedures, Surgical instruments, Surgery, Surgical procedures and techniques, Digestive system surgery

Grant

Application Date

5/23/2016

Grant Date

11/28/2017

Title

Related Topics

Surgical removal procedures, Surgical instruments, Surgery, Surgical procedures and techniques, Digestive system surgery

Status

Grant

Latest Dextera Surgical News

Surgical Stapling Devices Market 2016-2026 by Top Key Players- Johnson & Johnson Services, Inc., Medtronic plc, 3M Company, Dextera Surgical Inc., Meril Life Sciences Pvt. Ltd.

Jun 17, 2021

. Ltd. “Surgical Stapling Devices Market: Global Industry Analysis and Opportunity Assessment 2016-2026,” a recently published Future Market Insights report for the projected period of 10 years focusses on the performance of the global surgical stapling devices market. While drafting this report, our analysts have understood the need for a comprehensive study of the global surgical stapling devices market to penetrate and sustain in a price sensitive global market. According to them, the study of the market scenario will provide insights into the business opportunities. While conducting an in-depth study of this market, we found that key players in the global surgical stapling devices market are focussing on tapping the emerging markets in order to increase market share and increase the consumer base through exclusive product launches in emerging markets. New entrants are also focussing on tapping into emerging markets by introducing cost-effective surgical stapling devices. In a bid to increase their customer base, market competitors are concentrating on implementing value addition programmes. Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-867 Our analysts have taken a deep dive into the target segments and have observed that North America represents the most lucrative market, followed by Europe and APAC. After a detailed study of the market, we have also observed that the powered surgical stapling devices segment contributes significant market share and is the fastest growing segment due to advanced technology and high demand for the product on the global front. Apart from this, insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global surgical stapling devices market have been presented in this report. We have segmented the global surgical stapling devices market into six sections. They are as follows: By Region Our uniqueness lies in systematic exhaustive secondary research of the market Future Market Insights performs systematic exhaustive secondary research to analyse the required data points to arrive at the overall market numbers. We have developed a list of market players across the value chain i.e. technology developers, manufacturers, distributors, etc. We have also developed questionnaires for each node in the value chain to extract the required market information through primary research interviews. During our primary research, we have taken the help of various professional sites, while during secondary research we have followed the websites and annual reports of various companies. Our analysts have also studied company financial reports and white papers to get a fair idea of the current scenario of the global surgical stapling devices market. We have also taken inputs from some paid publications such as Factiva, GBI, Genios, Meltwater, Morningstar and Bureau Van Dijk for a detailed study of the global surgical stapling devices market. To understand key market segments in terms of their growth and performance in the global surgical stapling devices market, Future Market Insights has developed a market attractiveness index. The resulting index would help providers identify existing market opportunities. Request for Report Ask A Question @ https://www.futuremarketinsights.com/ask-question/rep-gb-867 Structure of the report Our comprehensive report on the global surgical stapling devices market includes an executive summary and a market overview which consists of market introduction, taxonomy and market dynamics. Other elements such as market share analysis, market Y-o-Y growth, segment wise forecast and market attractiveness analysis have been taken into consideration while analysing the global surgical stapling devices market. The competitive landscape has been included to provide a dashboard view of key companies operating in the global surgical stapling devices market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment in the global surgical stapling devices market and the potential players. This segment also includes market strategies and SWOT analysis of the main players operational in the global surgical stapling devices market. Detailed profiles of surgical stapling devices manufacturers are also included in the scope of the report to evaluate their long- and short-term strategies. Explore Wide-ranging Coverage of FMI’s HealthcareLandscape Mammalian Transient Protein Expression Market  –The mammalian transient protein expression market has reflected steady growthon the back of growing demand from the biomedicine sector. Efforts into vaccinedevelopment continue to create possibilities for new opportunities. In Vitro Fertilization Banking Services Market  –According to the Centers for Disease Control and Prevention (CDC), about 10% ofwomen in the United States between ages 15 to 44 years have infertility whilethe rate of male infertility is 4.5-6% in North America. Cryopreservation for In-vitro Fertilization (IVF) Market  –According to analysis by Future Market Insights (FMI), cryopreservationfor IVF market surpassed a valuation of US$ 339 million in 2019. Themarket is set to reflect an impressive 10.2% CAGR through 2030. About FMI        Future Market Insights (FMI) is a leading provider of marketintelligence and consulting services, serving clients in over 150countries. FMI  isheadquartered in Dubai, the global financial capital, and has delivery centersin the U.S. and India. FMI’s latest  marketresearch reports  and industry analysis help businesses navigatechallenges and make critical decisions with confidence and clarity amidst breakneckcompetition. Our customized and syndicated market research reports deliveractionable insights that drive sustainable growth. A team of expert-ledanalysts at FMI continuously tracks emerging trends and events in a broad rangeof industries to ensure that our clients prepare for the evolving needs oftheir consumers. ContactUs

Dextera Surgical Frequently Asked Questions (FAQ)

  • When was Dextera Surgical founded?

    Dextera Surgical was founded in 1997.

  • Where is Dextera Surgical's headquarters?

    Dextera Surgical's headquarters is located at 900 Saginaw Drive, Redwood City.

  • What is Dextera Surgical's latest funding round?

    Dextera Surgical's latest funding round is Acquired.

  • How much did Dextera Surgical raise?

    Dextera Surgical raised a total of $11.87M.

  • Who are the investors of Dextera Surgical?

    Investors of Dextera Surgical include Aesculap, Sutter Hill Ventures, Wasatch Advisors, Cross Creek, Wells Fargo and 4 more.

  • Who are Dextera Surgical's competitors?

    Competitors of Dextera Surgical include Avertix, NeoChord, Spectrum Medical, Clearflow, Mitralign and 7 more.

Loading...

Compare Dextera Surgical to Competitors

A
Arbor Surgical Technologies

Arbor Surgical Technologies, Inc. with facilities located in Irvine and Portola Valley, CA (USA), is a privately held cardiovascular medical device company focused on the heart valve replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted heart valve designer, Ernie Lane, Arbor is developing multiple technologies that have the potential to deliver significant clinical benefit to patients worldwide. Arbor intends to develop and commercialize its core technologies in varying combinations, giving the company the opportunity to create a broad portfolio of product offerings. Currently in clinical trials, Arbor is developing a tissue heart valve family of products designed for improved performance over existing valves and compatible implantation tools that simplify and speed valve replacement surgery. Arbor Surgical Technologies mission is to simplify cardiac valve surgery through the innovative development of a less invasive, unique implantation system and valves with superior performance and durability. Partnering with physicians, we will improve patient recovery by less invasive techniques and reduced surgery time. Ethical behavior with employees, surgeons, patients and suppliers is the keystone to our success.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.

S
Spectrum Medical

Spectrum Medical focuses on the domain of perfusion systems and clinical information solutions. The company offers medical device connectivity technologies, electronic medical record systems, telemedicine capabilities, and compliance and patient safety solutions, as well as non-invasive diagnostic systems for extracorporeal procedures. Spectrum Medical primarily serves the healthcare industry. It was founded in 2007 and is based in Gloucester, United Kingdom.

Avertix Logo
Avertix

Avertix develops an implantable cardiac monitoring and alerting system to warn cardiac patients of potentially life-threatening heart conditions. It offers heart monitors that track changes in the heart's electrical signal from a pacemaker lead. It identifies the symptoms of acute thrombotic occlusions by alerting the patient to seek medical attention. The firm was formerly known as Angel Medical Systems and changed its name to Avertix in April 2023. The company was founded in 2001 and is based in Eatontown, New Jersey.

A
Axis Surgical Technologies

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.

Clearflow Logo
Clearflow

Clearflow is a company focused on improving patient outcomes in the medical sector, specifically in cardiac surgery. The company offers sustainable medical technologies that help prevent complications due to retained blood after heart and lung surgeries, such as blood clot obstructions in chest tubes. These technologies enable healthcare professionals to manage postoperative bleeding in a safe, reliable, and efficient manner. Clearflow was formerly known as Clear Catheter Systems. It was founded in 2007 and is based in Anaheim, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.